Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment
Study Number: 

P 47916

Phase: 
2
Principal Investigator: 
Igor Puzanov, MD, MSCI, FACP

Check your eligibility for this trial.

Official Title: 
A Multicenter Phase 2, Adaptive, Open-Label Trial of Intratumoral pIL-12 plus Electroporation in Combination with Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment
Purpose: 
This will be a Phase 2 study of intratumoral tavokinogene telseplasmid (tavo; pIL-12) Electroporation (EP) plus IV Pembrolizumab. Eligible patients will be those with pathological diagnosis of unresectable or metastatic melanoma who are progressing or have progressed on pembrolizumab or nivolumab.
ClinicalTrials.Gov ID: 
NCT03132675
Learn more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.